Effect of Proliferator-Activated Receptor-γ Pro12Ala Polymorphism on Colorectal Cancer Risk: A Meta-Analysis

Zhijiang Wei
Guoda Han
Xiyong Bai

Background: The association between peroxisome proliferators-activated receptor γ (PPARγ) Pro12Ala polymorphism and colorectal cancer (CRC) risk is still controversial. A meta-analysis was performed.

Material/Methods: We conducted a literature search using PubMed, EMBASE, and Cochran databases. The pooled odds ratio (OR) with 95% confidence intervals (CIs) were calculated. Fixed-effects and random-effects models were used. Dominant model, recessive model, and additive model were used in this meta-analysis.

Results: Fifteen studies including 13575 cases and 17085 controls were included in our meta-analysis. Result of this meta-analysis found that PPARγ Pro12Ala polymorphism was significantly associated with a reduced risk of CRC (OR=0.90; 95% CI 0.83–0.98; P=0.01). No significant association was found between PPARγ Pro12Ala polymorphism and CRC risk in Asians (OR=0.80; 95% CI 0.60–1.09; P=0.15). However, PPARγ Pro12Ala polymorphism was significantly associated with a reduced risk of CRC in Caucasians (OR=0.91; 95% CI 0.83–0.99; P=0.03). When stratified analysis was performed by CRC site, no positive association was found between PPARγ Pro12Ala polymorphism and rectal cancer (OR=0.95; 95% CI 0.74–1.22; P=0.71). However, a reduced risk of colon cancer was observed (OR=0.85; 95% CI 0.76–0.94; P=0.002).

Conclusions: In summary, this study suggests that PPARγ Pro12Ala polymorphism was a protective factor of CRC.

MeSH Keywords: Colorectal Neoplasms • Genetic Association Studies • Meta-Analysis

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/892849
Background
Colorectal cancer (CRC) is a common digestive tumor; the incidence of CRC is just lower than gastric and esophageal cancer. More than one million new cases of CRC were diagnosed globally each year [1]. CRC is becoming a very urgent public health concern, especially in the developed countries. In USA, the incidence rate and mortality rate of CRC ranked third among all tumors in both men and women [2]. Body mass index, height, smoking status, and alcohol use have been reported to be associated with CRC risk [3]. However, the pathogenesis of CRC is still uncertain. Identification of related genetic variants could elucidate mechanisms underlying this disease.

Peroxisome proliferators-activated receptors (PPAR), which have PPARα, PPARβ/δ and PPARγ, are members of the nuclear receptor superfamily of ligand-activated transcription factors [4]. Due to its association with many human cancers such as colon, thyroid, breast, and prostate, PPARγ has been suggested to be an attractive target for cancer therapy [4]. Although the PPARγ nuclear receptor pathway was involved in cancer development, it might appear to have both oncogenic and tumor suppressor functions. Sarraf et al. showed that ligand activation of PPAR in colon cancer cells could cause a considerable reduction in linear and clonogenic growth, increase expression of carcinoembryonic antigen, and the reversal of many gene expression events specifically associated with colon cancer [5]. However, Saez et al. suggested that PPAR activation may provide a molecular link between a high-fat diet and increased risk of CRC [6].

A common polymorphism in the PPARγ, CCA→GCA, causing a Pro→Ala substitution at codon 12 (Pro12Ala), has been reported. The Pro12Ala polymorphism has been suggested to be associated with decreased receptor activity, lower body mass index, and improved insulin sensitivity [7]. The Pro→Ala change might cause a conformational change in the PPARγ protein, and thus affect its activity. Several studies have reported the association between PPARγ Pro12Ala polymorphism and CRC risk [8–22]. However, the results were still equivocal. Recently, a meta-analysis with nine studies found that this polymorphism was not associated with CRC risk [23]. However, six case-control studies were published and not all studies supported that result. Therefore, we performed a meta-analysis of all eligible studies to evaluate the association between PPARγ Pro12Ala polymorphism and CRC risk.

Material and Methods
Material
We conducted a literature search using PubMed, EMBASE, and Cochran databases. The following terms were used: “colorectal neoplasms” or “colorectal cancer”) and (“PPARγ” or “peroxisome proliferators-activated receptor γ”). The last search was updated on December, 2014. All searched studies were retrieved and only published studies with full-text articles were included. In duplicate samples, only the largest study was used in this research.

Inclusion/exclusion criteria
The inclusion criteria was as follows: (1) a case-control study or a cohort study; (2) the study evaluated the association between PPARγ Pro12Ala polymorphism and CRC risk; (3) the PPARγ Pro12Ala genotypes were provided.

The exclusion criteria were as follows: (1) animal studies; (2) not relevant to CRC or PPARγ; (3) reviews or abstracts; (4) not offer enough data.

Data extraction
Two authors extracted the following data: first author, year, race, sample size, and genotype distribution. The disagreements were resolved by consensus.

Statistical analysis
Statistical analysis was all conducted using Stata software 11.0 (StataCorp, College Station, Texas, USA). HWE test in healthy control group was conducted using χ² test. Odds ratio (OR) with a 95% confidence interval (CI) was presented for dichotomous data, and significance level was 0.05. Dominant model, recessive model, and additive model were used in this meta-analysis. Q-statistic and I²-statistic were used to measure statistical heterogeneity and significance level was 0.10. Effect model selection was on the basis of heterogeneity test. Fixed-effect models was selected when no significant heterogeneity, otherwise we used the random-effects model. Subgroup analyses were carried out based on race and cancer site. To evaluate the reliability of the results, one-way sensitivity analyses and cumulative meta-analysis were performed. Publication bias was investigated by the method of Egger’s test. The two-sided P<0.05 was considered statistically significant.

Results
Eligible studies
Figure 1 shows the study selection procedure. Based on the inclusion and exclusion criteria, 15 studies including 13575 cases and 17085 controls were included in our meta-analysis. Only three studies were performed in Asian populations, while other studies were performed in Caucasian populations. The characteristics of the included studies are listed in Table 1.
Quantitative synthesis

Result of this meta-analysis suggest that PPARγ Pro12Ala polymorphism was significantly associated with a reduced risk of CRC in dominant genetic model (OR=0.90; 95% CI 0.83–0.98; P=0.01; Figure 2). No significant association was found between PPARγ Pro12Ala polymorphism and CRC risk in Asians (OR=0.80; 95% CI 0.60–1.09; P=0.15). However, PPARγ Pro12Ala polymorphism was significantly associated with a reduced risk of CRC in Caucasians (OR=0.91; 95% CI 0.83–0.99; P=0.03). When stratified analysis was performed by CRC site, no positive association was found between PPARγ Pro12Ala polymorphism and rectal cancer (OR=0.95; 95% CI 0.74–1.22; P=0.71). However, a reduced risk of colon cancer was observed (OR=0.85; 95% CI 0.76–0.94; P=0.002). Results of other genetic models are listed in Table 2.

To evaluate the reliability of the results, we conducted cumulative meta-analysis by pooling the data, and each time one study was added. The results showed that the pooled ORs tended to be stable (Figure 3). We also performed the one-way sensitivity analysis by omitting studies one at a time. We found that any single study did not influence the pooled OR, suggesting that the results of this meta-analysis were robust (Figure 4). Moreover, no significant publication bias was found by funnel plot (Figure 5) and Egger’s test (P=0.12).

Table 1. Characteristics of case-control studies included in this meta-analysis of the association between the PPARγ Pro12Ala polymorphism and CRC risk.

| First author | Year | Ethnicity | No. of eligible subjects | Case | Control | Ala/Ala+Pro/Ala | Pro/Pro | Ala/Ala+Pro/Ala | Pro/Pro |
|--------------|------|-----------|--------------------------|------|---------|----------------|--------|----------------|--------|
| Landi        | 2003 | Caucasian | 360                      | 309  | 49      | 311            | 66     | 243            |
| Jiang        | 2005 | Asian     | 303                      | 293  | 63      | 240            | 63     | 230            |
| McGreavey    | 2005 | Caucasian | 455                      | 513  | 89      | 366            | 110    | 403            |
| Murtaugh     | 2005 | Caucasian | 2371                     | 2972 | 531     | 1840           | 689    | 2283           |
| Koh          | 2006 | Asian     | 362                      | 1164 | 17      | 345            | 89     | 1075           |
| Kuriki       | 2006 | Asian     | 127                      | 238  | 7       | 120            | 17     | 221            |
| Slattery     | 2006 | Caucasian | 2371                     | 2972 | 531     | 1840           | 689    | 2283           |
| Theodoropoulos | 2006 | Caucasian | 222                      | 200  | 58      | 164            | 82     | 118            |
| Vogel        | 2007 | Caucasian | 355                      | 753  | 103     | 252            | 203    | 550            |
| Küry         | 2008 | Caucasian | 811                      | 811  | 168     | 633            | 178    | 643            |
| Slattery     | 2009 | Caucasian | 1577                     | 1971 | 343     | 1234           | 478    | 1493           |
| Hawken       | 2010 | Caucasian | 1133                     | 1125 | 239     | 886            | 290    | 843            |
| Abuli        | 2011 | Caucasian | 515                      | 502  | 89      | 426            | 83     | 419            |
| Crous-Bou    | 2012 | Caucasian | 812                      | 1479 | 102     | 710            | 172    | 1307           |
| Sainz        | 2012 | Caucasian | 1801                     | 1783 | 447     | 1354           | 449    | 1334           |
Discussion

PPARγ Pro12Ala polymorphism has been reported to be associated with breast cancer, gastric cancer, and inflammatory bowel disease [24–26]. Lu et al. suggested that PPARγ Pro12Ala polymorphism was not associated with CRC risk [23]. However, a previous meta-analysis found that PPARγ Pro12Ala polymorphism might be a protective factor for CRC [26]. Thus, we did

### Table 2. Meta-analysis of association between the PPARγ Pro12Ala polymorphism and CRC risk.

| Study ID               | OR (95% CI)   | P value | I² | P value |
|------------------------|---------------|---------|----|---------|
| Dominant model         |               |         |    |         |
| All                    | 0.90 (0.83–0.98) | 0.01    | 42%| 0.04    |
| Asian                  | 0.80 (0.60–1.09) | 0.15    | 1% | 0.37    |
| Caucasian              | 0.91 (0.83–0.99) | 0.03    | 49%| 0.03    |
| Rectal                 | 0.95 (0.74–1.22) | 0.71    | 56%| 0.06    |
| Colon                  | 0.85 (0.76–0.94) | 0.002   | 0% | 0.45    |
| Recessive model        |               |         |    |         |
| All                    | 0.87 (0.79–0.94) | 0.001   | 32%| 0.35    |
| Asian                  | 0.94 (0.73–1.21) | 0.64    | 11%| 0.34    |
| Caucasian              | 0.87 (0.78–0.97) | 0.02    | 0% | 0.74    |
| Rectal                 | 0.87 (0.76–1.02) | 0.07    | 61%| 0.01    |
| Colon                  | 0.86 (0.74–0.99) | 0.04    | 39%| 0.37    |
| Additive model         |               |         |    |         |
| All                    | 0.84 (0.72–0.97) | 0.03    | 50%| 0.03    |
| Asian                  | 0.82 (0.62–1.12) | 0.34    | 21%| 0.22    |
| Caucasian              | 0.89 (0.80–0.96) | 0.01    | 34%| 0.33    |
| Rectal                 | 0.93 (0.72–1.20) | 0.65    | 43%| 0.08    |
| Colon                  | 0.83 (0.74–0.92) | 0.001   | 14%| 0.56    |

P<sub>ox</sub> and P<sub>Q</sub> refer to the significance levels of the odds ratio and Q-test of heterogeneity, respectively.

Lu et al. suggested that PPARγ Pro12Ala polymorphism was not associated with CRC risk [23]. However, a previous meta-analysis found that PPARγ Pro12Ala polymorphism might be a protective factor for CRC [26]. Thus, we did
this update meta-analysis to find the association between PPARγ Pro12Ala polymorphism and CRC risk. We found that PPARγ Pro12Ala polymorphism was significant associated with CRC risk, suggesting that PPARγ Ala allele carriers had reduced CRC risk compared to PPARγ Pro allele carriers. Furthermore, we found that this effect was only existed in Caucasians but not in Asians, suggesting a possible influence among different genetic backgrounds and environmental exposures, but these were only studies with Asians. More studies with Asians are needed to further investigate the association between PPARγ Pro12Ala polymorphism and CRC risk. Results from this meta-analysis found that PPARγ Pro12Ala polymorphism was only associated with colon cancer. It has been suggested that PPARγ activity was higher in the distal colon [27]; it is possible that the Ala/Ala+Pro/Ala genotypes had the greatest effect in the segment of the colon with the least PPARγ activity [28].

Ligands for the PPARγ have proven to be effective in preclinical models of CRC. Tanaka and coworkers indicated that administration of the PPARγ ligand troglitazone significantly reduces the number of aberrant crypt foci (ACF) lesions [29]. Aires et al. found that the combination of resveratrol with a PPARγ agonist could be a promising pharmacological approach for treatment of CRC [30]. Thus, PPARγ agonists combined with other chemotherapy drugs or other targeted therapies are worth pursuing in the treatment of CRC [31–36].

There were some limitations in this meta-analysis. First, the number of included studies was moderate. Therefore, the results could be influenced by random error. Second, CRC is a multifactorial disease, but the interactions among gene-environment and gene-gene were not considered in this meta-analysis. Third, other factors such as gender or diet habit may participate in the progression of CRC. However, we did not conduct subgroup analysis by these factors due to limited data.

Conclusions

In summary, this study suggested that PPARγ Pro12Ala polymorphism was a protective factor of CRC.

Disclosure of conflict of interest

None.
References:

1. Cunningham D, Atkin W, Lenz HJ et al: Colorectal cancer. Lancet, 2010; 375(9719): 1030–47
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. Cancer J Clin, 2012; 62(3): 10–29
3. Hutter CM, Chang-Claude J, Slattery ML et al: Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res, 2012; 72(8): 2036–44
4. Michalik L, Desvergne B, Wahli W: Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer, 2004; 4(1): 61–70
5. Sarraf P, Mueller E, Jones D et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med, 1998; 4(9): 1046–52
6. Saez E, Tontonoz P, Nelson MC et al: Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med, 1998; 4(9): 1058–61
7. Deeb SS, Fajas L, Nemoto M et al: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet, 1998; 20(3): 284–87
8. Landi S, Moreno V, Góia-Patrícia L et al, Bellvitge Colorectal Cancer Study Group: Association of common polymorphisms in inflammatory genes in terleukin (IL)6, IL8, tumor necrosis factor alpha, NFκB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res, 2003; 63: 3560–66
9. Ilang I, Gajalakshmi V, Wang J et al: Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population. Cancer Sci, 2005; 96: 507–12
10. McGreavey LE, Turner F, Smith G et al, Colorectal Cancer Study Group: No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics, 2005; 15: 713–21
11. Murtbaugh MA, Ma KN, Caan BJ et al: Interactions of peroxisome proliferator-activated receptor gamma and diet in etiology of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 2003; 12, 4, and 7) correlates with aggressive behavior in colorectal carcinoma. Mol Nutr Food Res, 2014; 58(9): 1785–94
12. Koh WP, Yuan JM, Van Den Berg D et al: Peroxisome proliferator-activated receptor (PPAR) gene polymorphisms and colorectal cancer risk among Chinese in Singapore. Carcinogenesis, 2006; 27: 1797–802
13. Kuriki K, Hirose K, Matsuo K et al: Meat, milk, saturated fatty acids, the Pro12Ala and C161T polymorphisms of the PPARgamma gene and colorectal cancer risk in Japanese. Cancer Sci, 2006; 97: 1226–35
14. Slattery ML, Curtin K, Wolff R et al: PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control, 2006; 17: 239–49
15. Theodoropoulos G, Papaconstantinou I, Felekouras E et al: Relation between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res, 2007; 624: 88–100
16. Vogel U, Christensen J, Dybdahl M et al: Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res, 2007; 624: 88–100
17. Küry S, Buecher B, Robiou-du-Pont S et al: Low-penetration alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study. BMC Cancer, 2008; B: 326
18. Slattery ML, Wolff RK, Curtin K et al: Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. Mutat Res, 2009; 660: 12–21
19. Hawken SJ, Greenwood CM, Hudson TI et al: The utility and predictive value of combinations of low penetrance genes for screening and risk prediction of colorectal cancer. Hum Genet, 2010; 128: 89–101
20. Abuli A, Fernández-Rodazilla C, Alonso-Espinaco V et al, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association: Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer, 2011; 11: 339
21. Crous-Bou M, Rennert G, Salazar R et al: Genetic polymorphisms in fatty acid metabolism genes and colorectal cancer. Mutagenesis, 2012; 27(2): 169–76
22. Sainz J, Rudolph A, Hoffmeister M et al: Effect of type 2 diabetes predisposing genetic variants on colorectal cancer risk. J Clin Endocrinol Metab, 2012; 97: E845–51
23. Lu Y, Li G, Huang HL et al: Peroxisome proliferator-activated receptor-gamma 34C>G polymorphism and colorectal cancer risk: a meta-analysis. World J Gastroenterol, 2010; 16: 2170–75
24. Zhang ZF, Yang N, Zhao G et al: Association between the Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma 2 and inflammatory bowel disease: a meta-analysis. PloS One, 2012; 7(1): e30551
25. Mao Q, Guo H, Gao L et al: Peroxisome proliferator-activated receptor 2 Pro12Ala (rs1801282) polymorphism and breast cancer susceptibility: a meta-analysis. Mol Med Rep, 2013, 8(6): 1773–77
26. Xu W, Li Y, Wang X et al: PPARgamma polymorphisms and cancer risk: a meta-analysis involving 32,138 subjects. Oncol Rep, 2010; 24(2): 579–85
27. Lefebvre M, Paulweber B, Fajas L et al: Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelial cells. J Endocrinol, 1999; 162(3): 331–40
28. Rangwala SM, Rhoades B, Shapiro JS et al: Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell, 2003; 5(4): 657–63
29. Tanaka T, Kohno H, Yoshitani S et al: Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res, 2001; 61(6): 2424–28
30. Aires V, Brassart B, Carlier A et al: A role for peroxisome proliferator-activated receptor gamma in prevention of colorectal cancer cell apoptosis. Mol Nutr Food Res, 2014; 58(9): 1785–94
31. Sümübl AT, Disel U, Sezgin N et al: Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiogenesis II (ANGII) levels have predictive role during Bevacizumab treatment? Med Sci Monit, 2014; 20: 428–33
32. Süren D, Yıldırım M, Demirgençe O et al: The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit, 2014; 20: 530–37
33. Süren D, Yıldırım M, Kaya V et al: Loss of tight junction proteins (Claudin 1, 4, and 7) correlates with aggressive behavior in colorectal carcinoma. Med Sci Monit, 2014; 20: 428–33
34. Gao L, Bai L, Nan Qz: Activation of Rho GTPase Cdc42 promotes adhesion and invasion in colorectal cancer cells. Med Sci Monit Basic Res, 2013; 19: 400–7
35. Płachetka A, Adamek B, Strzelczyk JK et al: 8-hydroxy-2'-deoxyguanosine (8-oxodG) in colorectal cells. Med Sci Monit, 2012; 18(6): BR237–46
36. Han DP, Zhu QL, Cui JT et al: Polo-like kinase 1 is overexpressed in colorectal cancer cells. Med Sci Monit, 2013; 19: 201–7
37. Gao L, Bai L, Nan Qz: Activation of Rho GTPase Cdc42 promotes adhesion and invasion in colorectal cancer cells. Med Sci Monit, 2014; 20: 428–33
38. Plachetka A, Adamek B, Strzelczyk JK et al: 8-hydroxy-2'-deoxyguanosine (8-oxodG) in colorectal cancer cells. Med Sci Monit, 2012; 18(6): BR237–46